Genetic susceptibilities and prediction modeling of carbamazepine and allopurinol-induced severe cutaneous adverse reactions in Vietnamese-Reference-Cited by-全球学者库

Genetic susceptibilities and prediction modeling of carbamazepine and allopurinol-induced severe cutaneous adverse reactions in Vietnamese

Published:2021-01 Issue:1 Volume:22 Page:1-12
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

van Nguyen Dinh¹²³⁴,Chu Hieu Chi⁵,Vidal Christopher³,Fulton Richard B⁴,Nguyen Nguyet Nhu⁵,Quynh Do Nga Thi⁶,Tran Tu Linh⁷,Nguyen Thuy Ninh⁷,Thu Nguyen Ha Thi⁸,Chu Hanh Hong⁹,Thanh Thuc Huyen Thi⁹,Minh Le Huong Thi⁹,van Nunen Sheryl³¹⁰,Anderson Janet⁴^ORCID,Fernando Suran L³⁴¹⁰

Affiliation:

1. Vinmec Healthcare System, Hanoi, 100000, Vietnam

2. College of Health Science, VinUniversity, Hanoi, 100000, Vietnam

3. Sydney Medical School - Northern, The University of Sydney, Sydney, 2065, Australia

4. ImmunoRheumatology Laboratory, NSW Health Pathology-North, Royal North Shore Hospital, Sydney, 2065, Australia

5. Center of Allergology & Clinical Immunology, Bach Mai Hospital, Hanoi, 115000, Vietnam

6. Department of Immunology & Molecular Biology, National Institute of Hygiene & Epidemiology, Hanoi, 100000, Vietnam

7. Hanoi Heart Hospital, Hanoi, 100000, Vietnam

8. Department of Allergy & Clinical Immunology, Hanoi Medical University, Hanoi, 100000, Vietnam

9. Department of Allergy, Immunology & Rheumatology, National Hospital of Pediatrics, Hanoi, 100000, Vietnam

10. Department of Clinical immunology & Allergy, Royal North Shore Hospital, Sydney, 2065, Australia

Abstract

Aims: To determine genetic susceptibility markers for carbamazepine (CBZ) and allopurinol-induced severe cutaneous adverse reactions (SCARs) in Vietnamese. Methods: A case–control study was performed involving 122 patients with CBZ or allopurinol-induced SCARs and 120 drug tolerant controls. Results: HLA-B*58:01 was strongly associated with allopurinol-induced SCARs and strongly correlated with SNP rs9263726. HLA-B*15:02 was associated with CBZ-induced Stevens–Johnson syndrome/toxic epidermal necrolysis but not with drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms. No association was found between HLA-A*31:01 and CBZ-induced SCARs. HLA-B*58:01 and rs3909184 allele A with renal insufficiency were shown to increase the risk of allopurinol-induced SCARs. Conclusion: HLA-B*58:01 and HLA-B*15:02 confer susceptibility to allopurinol-induced SCARs and CBZ-induced SJS/TEN in Vietnamese. SNP rs9263726 can be used as a surrogate marker in identifying HLA-B*58:01.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2019-0146

Reference50 articles.

1. Severe Adverse Cutaneous Reactions to Drugs

2. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study

3. Trends in the use of antiepileptic drugs in Taiwan from 2003 to 2007: A Population-Based National Health Insurance study

4. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population

5. Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on HLA-B*15:02 allele associated with adverse drug reactions;Pharmacogenomics;2024-02-02

2. Unravelling the Genetic Link: An Umbrella Review on HLA-B∗15:02 and Anti-Epileptic Drug-induced Stevens–Johnson Syndrome / Toxic Epidermal Necrolysis;2023-09-19

3. Cost–effectiveness of HLA-B*58:01 testing to prevent Stevens–Johnson syndrome/toxic epidermal necrolysis in Vietnam;Pharmacogenomics;2023-08

4. The pharmacogenomics of carbamazepine-induced cutaneous adverse drug reaction in the South of Vietnam;Frontiers in Pharmacology;2023-07-13

5. Role of human leukocyte antigen in anti-epileptic drugs-induced Stevens–Johnson Syndrome/toxic epidermal necrolysis: A meta-analysis;Seizure;2022-11